Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVXL Stock Price Chart Interactive Chart >
AVXL Price/Volume Stats
|Current price||$10.87||52-week high||$15.24|
|Prev. close||$10.05||52-week low||$7.13|
|Day high||$10.89||Avg. volume||1,302,433|
|50-day MA||$9.79||Dividend yield||N/A|
|200-day MA||$10.18||Market Cap||847.45M|
Anavex Life Sciences Corp. (AVXL) Company Bio
Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimers disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.
Most Popular Stories View All
AVXL Latest News Stream
|Loading, please wait...|
AVXL Latest Social Stream
View Full AVXL Social Stream
Latest AVXL News From Around the Web
Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett Syndrome. Let's see why it's a favorite for 2023.
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
AVXL Price Returns